Articles tagged with Prostate Tumors
Researchers found that intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events triggered by cellular senescence, providing proof-of-principal for a new treatment paradigm. The study shows that once disrupted, it takes time for the inflammatory loop to reestablish, offering hope for a safer and more effe...
The Scripps Proton Therapy Center in San Diego is reporting exceptional results in delivering cancer treatment using pencil-beam scanning technology, enabling the treatment of a wide range of tumor sites. The center has treated patients with lung, brain, spinal column, and other tumors, offering greater precision and efficiency in radi...
Researchers at the University of Chicago have identified a cell-intrinsic cancer-causing pathway that disrupts T cell infiltration in melanoma, enabling tumors to evade immune surveillance. Disrupting this signaling pathway could help restore T cell access and enhance the potential of immune-mediated cancer treatment.
Research led by Kansas State University's Brad Behnke suggests that moderate exercise can enhance tumor oxygenation, potentially improving the effectiveness of cancer treatments. Moderate-intensity exercise has been shown to increase oxygen delivery to tumors, making them more susceptible to radiation therapy.
Researchers found that blocking immune-suppressing cells allows chemotherapy to destroy prostate tumors in mouse models, achieving near complete remission. This novel combination therapy may have broader applications for other cancer types due to its effectiveness against metastatic and unresponsive cancers.
Researchers found that vitamin D supplements slowed tumor growth and reduced inflammation in men with low-grade prostate cancer. The study suggests that vitamin D may improve treatment outcomes for these patients by reducing the need for aggressive treatments.
Researchers found that MED15 overexpression is associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors. MED15 may serve as a prognostic marker for HNSCC recurrence and as a therapeutic target in HNSCC patients suffering from recurrences.
Researchers developed a customized genetic construct using tiny DNA minicircles to detect cancer in mice. The technique uses a protein called secreted embryonic alkaline phosphatase, which is not produced in adults but is present in embryos.
Scientists have created a conjugate molecule that targets and suppresses prostate cancer growth in mice, using a near-infrared dye and MAO-A inhibitor. The compound NMI shows promise as a therapeutic and diagnostic tool for prostate and other cancers.
Researchers at CNIC identified the molecular mechanism regulating transport of Rac1 between nucleus and cytoplasm. Sustained presence of Rac1 in nucleus promotes nuclear deformation to facilitate cell migration through confined spaces. The study provides potential targets for future therapies.
A novel imaging technique called restriction spectrum imaging-MRI (RSI-MRI) has been developed to improve the accuracy of prostate cancer detection. RSI-MRI corrects for magnetic field distortions and focuses on water diffusion within tumor cells, providing a more refined sense of the tumor's extent.
Researchers at MD Anderson Cancer Center have identified a protein complex called CSN and its subunit CSN6 as a key factor in cancer development. The study found that inhibiting CSN6 can quickly destabilize the master cancer gene Myc, greatly impairing tumor growth and metastasis.
Conventional treatments such as surgery and radiotherapy are less effective in prostate cancer patients carrying BRCA mutations, resulting in lower survival rates. The study suggests that targeted therapy, like PARP inhibitors, may be a more suitable option for these patients.
A molecular breakthrough has identified a compound that can inhibit the activity of SRPK1, a molecule key to tumor formation and blood vessel creation. This process is essential for cancer cell survival and multiplication.
Prostate cancer cells hoard copper, and researchers have found a way to deliver a trove of copper along with a drug that selectively destroys the diseased cells. This combination approach could lead to improved treatments for late-stage disease.
A new study published in Endocrinology found that testosterone treatment increased the incidence of prostate carcinomas in rats. The research suggests that testosterone alone is a weak carcinogen in male rats and creates a hospitable environment for tumors to develop when combined with cancer-causing chemicals.
Researchers matched 25 patients' treatment outcomes with their tumor's RNA sequence, finding similarities that could aid diagnosis and predict effective treatment. The study suggests that RNA sequencing may be a useful tool to aid personalized medicine in prostate cancer.
A team of scientists found that losing p62 in surrounding cells enhances tumor growth and progression. The study suggests therapies targeting the tumor microenvironment may be as important as targeting the tumor itself.
Two new genes, FOXM1 and CENPF, linked to more aggressive prostate cancer have been discovered. A new approach in the treatment of these patients is being developed using computer algorithms and biomarkers.
A new method using existing ultrasound scanners allows doctors to accurately detect prostate cancer with much greater precision, reducing the need for painful biopsies. The technique saves money by eliminating costly biopsy analysis and can potentially eliminate biopsies altogether.
Researchers have discovered a feedback loop between IL-6 and microRNA-34a that promotes tumor cell mobility and metastasis. The loop involves the activation of STAT3, which represses miR-34a production and leads to increased tumor-promoting proteins.
Researchers found that injecting a virus directly into one melanoma tumor can induce a potent anti-tumor immune response, destroying both infected and non-infected tumors. This combination therapy overcomes the limitations of oncolytic virotherapy and checkpoint blockade.
Research suggests that walking at a brisk pace prior to diagnosis may improve prostate cancer outcomes by having more regularly shaped blood vessels. Men with faster walking paces had 8% more regularly shaped blood vessels compared to those with slower paces.
Researchers will investigate racial and ethnic differences in IRDS-positive tumors prevalent in African-Americans to improve outcomes for patients with treatment-resistant prostate cancer. The study aims to identify new management and treatment options for this aggressive disease.
A study led by Beth Israel Deaconess Medical Center researchers found that carbon monoxide can prevent tumor growth and amplify chemotherapy's effects, sparing healthy tissue. The findings suggest CO induces an 'anti-Warburg' effect, fueling cancer cell bioenergetics until metabolic exhaustion.
A new study found that men with a specific genetic mutation are more than 50% likely to die from prostate cancer if they're overweight or obese. The researchers analyzed data on 1,243 participants and discovered that obesity was linked to higher levels of insulin and growth factor receptors in tumors containing the mutation.
Researchers discovered that selective inhibition of nuclear export protein CRM1 can reactivate tumor suppressor proteins in cells, leading to cancer cell death. This approach shows promise for treating advanced prostate cancers.
Researchers found that geranylgeraniol suppressed human DU145 prostate carcinoma cell viability via cell cycle arrest at the G1 phase and apoptosis initiation. The compound also down-regulated HMG CoA reductase, a key enzyme in the mevalonate pathway.
A new three-gene biomarker can accurately predict which low-risk prostate cancers will become aggressive, helping doctors determine whether men need active surveillance or invasive treatment. The test has shown promising results in a retrospective study of 43 patients, and further clinical trials are planned.
A new GE technology uses pyruvate levels to detect prostate tumors in real time, providing a safe and non-invasive way to assess cancer progression. The technology has shown promising results in a clinical study of 31 patients with prostate cancer.
A study found that a walnut-enriched diet reduced prostate cancer formation by 18% and slowed tumor growth. The results suggest that using walnuts on a regular basis may be beneficial in deferring or preventing certain types of cancer, including breast cancer.
Researchers at Albert Einstein College of Medicine have found that nerves play a critical role in both the development and spread of prostate tumors. The study suggests that targeting the autonomic nervous system may lead to novel therapies for preventing and treating prostate cancer.
Researchers at Cedars-Sinai Medical Center have uncovered the crucial role of Caveolin-1 protein in prostate cancer tumor microenvironment. A decreased level of this protein in the stroma indicates worse prognosis and higher chance of disease relapse.
Researchers used next-generation sequencing to analyze DNA alterations in adjacent Gleason patterns of the same tumor. The study found that some aggressive prostate cancers have identical genetic markers, enabling better prediction of cancer progression and management.
Researchers have identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer. The findings suggest a potential new approach to blocking metastasis in various cancers.
Scientists at the University of Michigan have decoded the molecular signals that enable cancer cells to spread throughout the body. By understanding how tumor cells recruit healing cells, researchers can now develop drugs to block these messages and prevent metastasis.
Researchers are working on a technique that can help identify and treat cancer tumors using manganese-enhanced magnetic resonance imaging (MEMRI). The goal is to guide and individualize treatment based on the presence of specific calcium channels in tumors.
Researchers at Massachusetts General Hospital identified a genetic signature associated with the risk of tumor recurrence or spread in men surgically treated for prostate cancer. The 32-gene index proved to be the most accurate method, predicting actual incidence of tumor recurrence (47%) and metastasis (14%) among high-risk patients.
A recent study found that tumor boards have a modest association with the types of treatments patients receive for certain cancers. For example, lung cancer and prostate cancer patients were more likely to receive higher-quality care when treated at hospitals with tumor boards. However, other types of cancer care remained unaffected by...
A new targeted prostate biopsy technique using magnetic resonance ultrasound fusion has been shown to improve diagnosis of prostate cancer and aid in selecting patients for active surveillance. The study found that the biopsies identified 90 out of 171 men with prostate cancer, highlighting its potential as a more accurate and efficien...
Researchers found that high levels of COUP-TFII can overcome a natural barrier to prostate cancer progression, allowing tumor cells to grow and spread throughout the body. The study suggests that COUP-TFII is an important 'second hit' for the progression of prostate cancer and metastasis.
Resveratrol, a compound found in grape skins and red wine, has been shown to increase the susceptibility of prostate tumor cells to radiation treatment, leading to higher mortality rates. This discovery offers new hope for developing effective treatments for all types of prostate cancer, including aggressive tumors.
A study of almost 1,000 men diagnosed with prostate cancer found that active surveillance can reduce or avoid side effects such as incontinence and impotence. Many low-risk tumours are slow-growing and may never develop symptoms during a lifetime.
Researchers have developed biodegradable iron-doped silica spheres to tag breast tumors, reducing the need for follow-up surgeries by up to 50%. The particles can be used to destroy tumor tissue with high-intensity focused ultrasound therapy, improving surgical precision and patient trauma.
A University of Colorado study shows that bladder cancer patients with high CD24 expression have worse prognoses and may benefit from anti-androgen therapies. CD24 expression depends on androgens, and blocking these hormones may diminish the proliferative and metastatic power of bladder cancer cells.
Research reveals that tumor hypoxia drives aggressive behavior and poorer prognosis in various cancers. CD24 overexpression is linked to tumor growth and metastasis, making it a potential therapeutic target.
Researchers identify a subpopulation of cancer stem cells that display resistance to chemotherapy and contribute to tumor progression. The study suggests a new therapeutic strategy by targeting these cancer stem cells with a combination of standard chemotherapy and signaling pathway inhibitors.
Researchers at the University of Texas Health Science Center San Antonio have discovered that RSV selectively kills cancer cells, with minimal side effects compared to traditional treatments. The virus is expected to be safe due to its childhood origins and limited lung infection.
Researchers found that fusion-negative prostate cancers have different DNA methylation patterns than healthy cells, with increased EZH2 enzyme activity. This discovery may lead to more specific treatments and improved diagnosis for prostate cancer patients.
Researchers have developed a method to find and kill malignant cells while sparing healthy ones using theranostic imaging. The technique relies on binding a potent drug therapy to specific proteins on tumor cell surfaces, allowing it to target cancerous cells with precision.
Researchers at Bangor University discovered a switch in cells that helps kill tumors with heat, which combines with an anti-cancer drug to treat localized cancers. The novel protein produced by heat modulates survival systems, and its discovery may improve heat-treatment of cancer for patients.
Researchers have found a new treatment for prostate cancer using gold nanoparticles produced from chemicals in tea leaves, reducing tumors by 80 percent and requiring doses thousands of times smaller than chemotherapy. The nanoparticles are attracted to tumor cells and destroy them efficiently.
The new proton therapy center will provide highly individualized treatments for cancer patients in the region, including pediatric and adult tumors. The center will be operated by UT Southwestern physicians and staff, with laboratory space for researchers and at least four treatment vaults.
The study published in Science Translational Medicine documents pre-clinical data and rationale for developing G-202 as a potential cancer therapy. G-202, combined with prodrug delivery, is effective at killing fast- and slow-growing cancers by targeting PSMA enzyme.
A new technique has been reported in the American Journal of Pathology that uses genetic abnormalities to predict prostate cancer relapse. The study found that copy number variations (CNVs) in both cancerous and non-cancerous tissues can accurately forecast recurrence, allowing for more targeted treatment approaches.
Researchers discovered a population of low-PSA prostate cancer stem cells that are resistant to hormone therapy and chemotherapy. These cells can differentiate into other cancer cell types and have long-term tumor-propagating capacity.
A compound isolated from honeybee hive propolis has been found to slow the growth of prostate cancer cells and tumors in mice by shutting down their system for detecting sources of nutrition. The compound CAPE arrests early-stage prostate cancer by suppressing proteins involved in cell proliferation, offering a promising co-treatment a...
Researchers at Thomas Jefferson University have discovered a powerful new strategy for personalized anti-cancer therapy by linking biomarker MCT4 to tumor metabolism. High levels of MCT4 are correlated with poorer overall survival and increased risk of recurrence in patients with triple negative breast cancer.
Researchers have discovered a new target for cancer therapy, TDO enzyme, which enables tumors to evade immune rejection. A novel inhibitor of TDO has shown promising results in preclinical studies.
Researchers at Trinity College Dublin have developed a new vaccine to treat cancer by manipulating the immune response. The vaccine, which has shown high effectiveness in pre-clinical trials, overcomes obstacles that have hindered previous cancer vaccines.